\
&
Contact us
\
&
Contact us
Published on | 4 years ago
ProgrammesDue to IT constraints in the budget calculation, all participants (beneficiaries and associated partners) must be encoded in SEP submission forms by clicking the button “Add partner”.
The distinction between “beneficiaries” and “associated partners” will be done at the Grant Agreement Preparation phase (GAP) for the proposals that will be retained for funding.
Legal entities located in Member States and Associated Countries (MS/AC) can be considered as associated partners during the GAP phase if a Letter of Commitment (LoC) was submitted in the proposal. These associated partners (MS/AC) must encode €0 costs in the budget table.
Legal entities located in non-associated Third Countries will be automatically considered as associated partners and must submit a Letter of Commitment (LoC) in the proposal.
Low to middle-income third countries listed in the Horizon Europe Programme Guide are eligible to receive funding and can encode costs in the budget table.
Note: For the 2021 call, applicants must submit Part B of their proposal as two separate documents: Part B1 and Part B2 (the correct link will be available in the forthcoming days).
Source: Funding and Tender Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
